{"prompt": "['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'procedures should be completed as indicated by the study protocol. If a clinically significant finding is identified', '(including, but not limited to changes from baseline) after enrollment, the investigator or qualified designee will', 'determine if any change in participant management is needed. Any new clinically relevant finding will be reported as an', 'adverse event (AE).', 'The data to be collected at the time of study intervention discontinuation will include the following:', 'If the study drug is discontinued, unless the subject withdraws consent, the participant will complete visit 17 (two weeks', \"post discontinuation) and visits 17-20. If the participant doesn't want to continue with the follow-up visit schedule\", 'detailed above, then it is important to complete a close-out visit.', 'Based on the known safety profiles of pegloticase and MMF and the procedures we have in place, we believe it is very', 'unlikely, but possible that we could witness one serious AE related to infection. We will institute a stopping rule for', 'safety re-evaluation that would occur if we register more than one such serious adverse reaction (eg. infection that', 'leads to hospitalization). We would then stop the study to comprehensively review safety and our study protocols in', 'conjunction with the DSMB. Other serious adverse reaction or deaths may or may not be related to the study and', 'stopping or discontinuation of the study will be considered on an individual basis. See Appendix 9 Data Safety', 'Monitoring Plan.', '8.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY', 'Participants are free to withdraw from participation in the study at any time upon request.', 'An investigator may discontinue or withdraw a participant from the study for the following reasons:', 'Pregnancy', 'Significant study intervention non-compliance', 'If any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such', 'that continued participation in the study would not be in the best interest of the participant', 'Disease progression which requires discontinuation of the study intervention', 'If the participant meets an exclusion criterion (either newly developed or not previously recognized) that', 'precludes further study participation', 'Participant unable to receive study intervention for 1 infusion period', 'The reason for participant discontinuation or withdrawal from the study will be recorded on the Study', 'Closeout/Withdrawl/Termination CRF. Participants who sign the informed consent form and are randomized but do not', 'receive the study intervention may be replaced.', '8.3', 'LOST TO FOLLOW-UR', 'A participant will be considered lost to follow-up if he or she fails to return for 2 scheduled visits and is unable to be', 'contacted by the study site staff.', 'The following actions will be taken if a participant fails to return to the clinic for a required study visit:', 'The study coordinator will attempt to contact the participant and reschedule the missed visit within the 10 day', 'window between pegloticase infusions and counsel the participant on the importance of maintaining the', 'assigned visit schedule and ascertain if the participant wishes to and/or should continue in the study.', 'Before a participant is deemed lost to follow-up, the investigator or designee will make every effort to regain', \"contact with the participant. These contact attempts should be documented in the participant's medical record\", 'or study file.', '15']['REduCing Immunogenicity to PegloticasE (RECIPE)', 'Protocol #Version v12: 13Jan2020', 'Should the participant continue to be unreachable, he or she will be considered to have withdrawn from the', 'study with a primary reason of lost to follow-up.', 'Based on our competitive enrollment of this study in the event a participant is lost to follow-up, withdraws', 'consent and discontinues the study before the end of week 12 and is therefore unable to contribute to the', 'primary outcome, the enrolling site will be afforded the opportunity to enroll a replacement participant.', '9', 'STUDY ASSESSMENTS AND PROCEDURES', 'This study will be coordinated by the University of Alabama at Birmingham (UAB). All study visits and procedures will be', 'performed at the United States, at UAB, the University of Michigan, and up to 6 to be named sites. Enrollment will be', 'competitive between sites. Frequency of study visits and clinical evaluations can be found in Table 1. Following the first', '12 week dual therapy phase, participants will be given an additional three months of open-label pegloticase only', 'therapy (see Figure 1) and will be followed to better understand the long-term efficacy (durability) of this approach,', 'which is essential for future studies. Specifically, we will whether assess the durability of the short course of MMF', 'continues over the next 12 weeks in the absence of MMF.', 'Participants will be seen according to schedule of visits and evaluations outlined in Table 1 and per the details that', 'follow:', 'Visit 1 - Screening Visit', 'The screening visit will take approximately 1 hour to complete. Potential participants will be screened to determine if', 'they satisfy all inclusion and exclusion criteria. Men and women 18 years of age or older will be invited to proceed with', 'informed consent (IC) and enroll in the study. At the screening visit, the study objectives will be explained to potential', 'participants. After all questions raised by a potential participant are answered, and before any protocol-specified', 'screening procedures are initiated, they will be offered the IC for the screening evaluation. A copy of the signed and', 'dated IC form must be provided to the participant. After IC is obtained, a participant number will be assigned. All', 'screening procedures must be completed and eligibility criteria met prior to start of immune-modulating therapy and', 'pegloticase infusions. Basic demographic information and reason(s) for exclusion must be completed on the specified', 'case report form (eCRF) pages for all participants who signed an ICF, but never received pegloticase. During the', 'screening visit, the following procedures will be performed, and information will be obtained to determine eligibility to', 'continue in this research study:', 'Review inclusion/exclusion criteria', 'ICF', 'Date of birth', 'Self-reported race/ethnicity', 'Medical history that might preclude study participation', 'Gout history and symptom severity', 'Medication review', 'Medication history (including use of over-the-counter medications [eg. aspirin], use of other', 'prescription medications including gout medications)', 'Dietary supplement/vitamin use', 'Vital signs', 'Physical exam includes, but is not limited to', 'Eye, Head, Ears, Nose, and Throat Exam (HEENT), and Neck', 'Cardiovascular', 'Dermatological', '16']\n\n###\n\n", "completion": "END"}